Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why ...

When funding is tight, life sciences startups must be even more strategic with requested amounts, timing, and funding sources ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Medical affairs can no longer afford to operate within legacy structures. Enter AI-enabled functional service provider (FSP) models that offer operational relief.

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to ...

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...

The life sciences industry is on the brink of a significant shift. Over the next few years, a historic patent cliff will reshape Big Pharma's landscape, triggering waves of talent movement between ...

Chris Garabedian, CEO of Xontogeny, a life science accelerator, discusses what other events provide value during the annual J.P. Morgan Healthcare conference (JPM), such as the Biotech Showcase. The ...

Six of the seven blockbuster biotherapeutics belonging to Big Pharma have roots to small biotechs (see Table 1). So too does Tim Charlebois, Ph.D., VP of technology and innovation strategy within ...